Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MGD024 |
| Synonyms | |
| Therapy Description |
MGD024 is a dual-affinity re-targeting (DART) molecule that targets both CD123 and CD3, which potentially leads to killing of tumor cells expressing CD123 and inhibition of tumor growth (Blood (2021) 138 (Supplement 1): 1165). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MGD024 | MGD-024|MGD 024 | CD123 (IL3RA) Antibody 14 | MGD024 is a dual-affinity re-targeting (DART) molecule that targets both CD123 and CD3, which potentially leads to killing of tumor cells expressing CD123 and inhibition of tumor growth (Blood (2021) 138 (Supplement 1): 1165). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05362773 | Phase I | MGD024 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | Recruiting | USA | 0 |